IP Library › Granted Patent US 12,606,869
Granted Patent B2
US 12,606,869 · App. 17/716,968 · Granted Apr 21, 2026

Methods for the administration of iloperidone

Inventors: Curt Wolfgang (Germantown, MD); Mihael Polymeropoulos (Potomac, MD); Christian Lavedan (Potomac, MD); Simona Volpi (Derwood, MD)
Assignee: Vanda Pharmaceutials Inc.
C12Q1/6883A61K31/135A61K31/4525A61K31/454A61K31/496A61P25/18C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,606,869
App. No.
17/716,968
Granted
Apr 21, 2026
Kind
B2
Abstract

The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.

Claims (42)

1 . A method for treating a patient with a compound that is iloperidone or a metabolite thereof, wherein the patient is suffering from schizophrenia, the method comprising the steps of:

determining that the patient demonstrates reduced CYP2D6-mediated metabolism relative to wild type by:

obtaining or having obtained a biological sample from the patient;

performing or having performed a genotyping assay on the biological sample; and

determining that the patient has a genotype associated with reduced CYP2D6-mediated metabolism, wherein the genotype includes two CYP2D6*41 alleles; and

administering the compound to the patient in a first amount that is one of 25%, 50%, or 75% of a second amount of 24 mg/day, that would be administered to a patient demonstrating CYP2D6-mediated metabolism consistent with a wild type CYP2D6 genotype, and

wherein a risk of QTc prolongation for the patient is lower following the administration of the first amount of the compound than it would be if the compound were administered in the second amount.

2 . The method of claim 1 , wherein the performing or having performed the genotyping assay step comprises:

extracting or having extracted genomic DNA or mRNA from the biological sample, and

sequencing or having sequenced CYP2D6 DNA derived from the extracted genomic DNA or from the extracted mRNA,

wherein the sequencing or having sequenced step further comprises:

amplifying or having amplified a CYP2D6 region in the extracted genomic DNA or mRNA to prepare a DNA sample enriched in DNA from the CYP2D6 gene region; and

sequencing or having sequenced the DNA sample by hybridizing the DNA sample to nucleic acid probes to determine if the patient has the genotype including two CYP2D6*41 alleles.

3 . The method of claim 1 , wherein the first amount of the compound is about 12 mg/day.

4 . A method of treating a patient who is suffering from a schizoaffective disorder, depression, Tourette's syndrome, a psychotic disorder or a delusional disorder, the method comprising:

determining that the patient has a genotype associated with reduced CYP2D6-mediated metabolism by:

obtaining or having obtained a biological sample from the patient, and

performing or having performed a genotyping assay on the biological sample to determine that the patient has a genotype associated with reduced CYP2D6-mediated metabolism, wherein the genotype includes two CYP2D6 *41 alleles; and

administering a compound that is iloperidone or a metabolite thereof to the patient in a first amount,

wherein the first amount of the compound is 25%, 50%, or 75% of a second amount of 24 mg/day of the compound that would be administered to a patient demonstrating CYP2D6-mediated metabolism consistent with a wild type CYP2D6 genotype,

wherein a risk of QTc prolongation for the patient is lower following the administration of the first amount of the compound than it would be if the compound were administered in the second amount.

5 . The method of claim 4 , wherein the patient is at risk for a prolonged QT interval.

6 . The method of claim 4 , wherein the first amount of the compound is about 12 mg/day.

7 . A method of treating a patient who is suffering from a schizoaffective disorder, depression, Tourette's syndrome, a psychotic disorder or a delusional disorder, the method comprising:

determining that the patient is at risk for iloperidone-induced QTc prolongation by:

obtaining or having obtained a biological sample from the patient, and

performing or having performed a genotyping assay on the biological sample to determine whether the patient has a CYP2D6 poor metabolizer genotype that includes two CYP2D6 *41 alleles, wherein the presence of the CYP2D6 poor metabolizer genotype indicates risk for iloperidone-induced QTc prolongation, and

administering a compound that is or a metabolite thereof, to the patient in a first amount,

wherein the first amount of the compound is one of 25%, 50%, or 75% of a second amount of 24 mg/day of the compound, wherein the second amount causes an iloperidone blood exposure level that is therapeutically effective in a patient not having a CYP2D6 poor metabolizer genotype.

8 . The method of claim 7 , wherein the patient is at risk for iloperidone-induced QTc prolongation.

9 . The method of claim 7 , wherein the first amount of iloperidone is about 12 mg/day.

10 . The method of claim 1 , wherein the compound comprises the metabolite of iloperidone, the metabolite being (1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl] propoxy]-3-methoxyphenyl] ethanol) (P88).

11 . The method of claim 1 , wherein the first amount of the compound is about 6 mg/day.

12 . The method of claim 1 , wherein the first amount of the compound is about 18 mg/day.

13 . The method of claim 4 , wherein the compound comprises the metabolite of iloperidone, the metabolite being (1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl] propoxy]-3-methoxyphenyl] ethanol) (P88).

14 . The method of claim 4 , wherein the first amount of the compound is about 6 mg/day.

15 . The method of claim 4 , wherein the first amount of the compound is about 18 mg/day.

16 . The method of claim 7 , wherein the compound comprises the metabolite of iloperidone, the metabolite being (1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl] propoxy]-3-methoxyphenyl] ethanol) (P88).

17 . The method of claim 7 , wherein the first amount of the compound is about 6 mg/day.

18 . The method of claim 7 , wherein the first amount of the compound is about 18 mg/day.

19 . The method of claim 1 , wherein the first amount of the compound is administered in twice daily (bid) divided doses.

20 . The method of claim 4 , wherein the first amount of the compound is administered in twice daily (bid) divided doses.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2022
From: WOLFGANG, CURT; POLYMEROPOULOS, MIHAEL; LAVEDAN, CHRISTIAN; VOLPI, SIMONA
To: VANDA PHARMACEUTICALS INC.
Reel/Frame 059563/0245 →
Continuity (5)
Continuation 16406229 · May 8, 2019
Continuation 14847784 · Sep 8, 2015
Continuation 14044183 · Oct 2, 2013
Continuation 12208027 · Sep 10, 2008
Related Publication 20220259660A1 · Aug 18, 2022
References Cited (141)
US 4965188A · Mullis et al. · 1990 [cited by applicant]
US 5130238A · Malek et al. · 1992 [cited by applicant]
US 5364866A · Strupczewski et al. · 1994 [cited by applicant]
US 5846717A · Brow et al. · 1998 [cited by applicant]
US 5981174A · Wolf et al. · 1999 [cited by applicant]
US 6001567A · Brow et al. · 1999 [cited by applicant]
US 7179597B2 · Woosley · 2007 [cited by applicant]
US 7767230B2 · Ahlheim et al. · 2010 [cited by applicant]
US 7799782B2 · Munson et al. · 2010 [cited by applicant]
US 7977356B2 · Grimler et al. · 2011 [cited by applicant]
US 8314129B2 · Grimler et al. · 2012 [cited by applicant]
US 8460867B2 · Kudaravalli et al. · 2013 [cited by applicant]
US 8586610B2 · Wolfgang · 2013 [cited by examiner]
US 8652776B2 · Lavedan et al. · 2014 [cited by applicant]
US 8999638B2 · Wolfgang et al. · 2015 [cited by applicant]
US 9057104B2 · Lavedan et al. · 2015 [cited by applicant]
US 9072742B2 · Lavedan et al. · 2015 [cited by applicant]
US 9074254B2 · Lavedan et al. · 2015 [cited by applicant]
US 9074255B2 · Lavedan et al. · 2015 [cited by applicant]
US 9074256B2 · Lavedan et al. · 2015 [cited by applicant]
US 9080214B2 · Lavedan et al. · 2015 [cited by applicant]
US 9138432B2 · Wolfgang et al. · 2015 [cited by applicant]
US 9157121B2 · Wolfgang et al. · 2015 [cited by applicant]
US 9243295B2 · Lavedan et al. · 2016 [cited by applicant]
US 9328387B2 · Lavedan et al. · 2016 [cited by applicant]
US 9408839B2 · Lavedan et al. · 2016 [cited by applicant]
US 10272076B2 · Wolfgang · 2019 [cited by examiner]
US 10563259B2 · Wolfgang et al. · 2020 [cited by applicant]
US 10563260B2 · Lavedan et al. · 2020 [cited by applicant]
US 10563261B2 · Lavedan et al. · 2020 [cited by applicant]
US 10570452B2 · Lavedan et al. · 2020 [cited by applicant]
US 10570453B2 · Lavedan et al. · 2020 [cited by applicant]
US 10874659B2 · Phadke et al. · 2020 [cited by applicant]
US 11071728B2 · Polymeropoulos · 2021 [cited by applicant]
US 11214827B2 · Polymeropoulos et al. · 2022 [cited by applicant]
US 11607408B2 · Smieszek et al. · 2023 [cited by applicant]
US 11723903B2 · Polymeropoulos · 2023 [cited by applicant]
US 12146185B2 · Polymeropoulos et al. · 2024 [cited by applicant]
US 20010034023A1 · Stanton, Jr. et al. · 2001 [cited by applicant]
US 20020022054A1 · Sawada et al. · 2002 [cited by applicant]
US 20020127561A1 · Bee et al. · 2002 [cited by applicant]
US 20030083485A1 · Milos et al. · 2003 [cited by applicant]
US 20030144220A1 · Obach · 2003 [cited by examiner]
US 20030170176A1 · Leyland-Jones · 2003 [cited by applicant]
US 20040072235A1 · Dawson · 2004 [cited by applicant]
US 20040091909A1 · Huang · 2004 [cited by applicant]
US 20040096874A1 · Neville et al. · 2004 [cited by applicant]
US 20040133352A1 · Bevilacqua et al. · 2004 [cited by applicant]
US 20050032070A1 · Raimundo · 2005 [cited by examiner]
US 20080166357A1 · Gotz et al. · 2008 [cited by applicant]
US 20220259660A1 · Wolfgang · 2022 [cited by examiner]
US 20230330078A1 · Wolfgang · 2023 [cited by examiner]
WO 0055624A2 · 2000 [cited by applicant]
WO 0149883A2 · 2001 [cited by applicant]
WO 0179554A1 · 2001 [cited by applicant]
WO WO2001079554A1 · 2001 [cited by examiner]
WO 0244994A2 · 2002 [cited by applicant]
WO 0250283A2 · 2002 [cited by applicant]
WO 02064141A1 · 2002 [cited by applicant]
WO 02099118A2 · 2002 [cited by applicant]
WO 03017946A2 · 2003 [cited by applicant]
WO 03038123A2 · 2003 [cited by applicant]
WO 03054226A3 · 2003 [cited by applicant]
WO 2004006886A2 · 2004 [cited by applicant]
WO 2004009760A2 · 2004 [cited by applicant]
WO 2004074456 · 2004 [cited by applicant]
Jain, K.K. Expert Opinion on Investigational Drugs 9(12):2935-2943. (Year: 2000). [cited by examiner]
L. Bertilsson et al., Molecular Genetics of CYP2D6: Clinical Relevance with Focus on Psychotropic Drugs, Br. J. Clin. Pharmacol. 53(2): 111-122 (2002). [cited by applicant]
Janssen Pharmaceutica Products, L.P., Risperdal® (Risperidone) tablets/oral solution; Risperdal® M-TAB™ (Risperidone) Orally Disintegrating Tablets Aug. 2007 Label, available at https://www.accessdata.fda.gov/drugsatfda… [cited by applicant]
Vanda Pharmaceuticals Inc., Fanapt Full Prescribing Information, Apr. 2024 Revision, available at https://fanaptpro.com/wp-content/uploads/Fanapt-Prescribing-Information.pdf (last visited Sep. 11, 2025), § 2.2 (Apr. 202… [cited by applicant]
Decision Denying Institution of Inter Partes Review, [cited by applicant]
U.S. Department of Health and Human Services, Food and Drug Administration (“FDA”), Guidance for Industry, In Vivo Drug Metabolism/Drug Interaction Studies—Study Design, Data Analysis, and Recommendations for Dosing and… [cited by applicant]
K. Brøsen, Differences in Interactions of SSRIs, Int. Clin. Psychopharmacol. Supp. 5:S45-47 (Sep. 1998). [cited by applicant]
N.E. Mealy et al., Annual Review 2002: Psychopharmacologic Drugs, Drugs of the Future 27(10):995-1027 (Oct. 2002). [cited by applicant]
U.S. Department of Health and Human Services, Food and Drug Administration (“FDA”), Guidance for Industry, Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro (Apr. 1997) (availabl… [cited by applicant]
R.R. Shah, Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes: Potential Tool for Improving Clinical Drug Development and Prescribing, Drug Safety 27(3):145-72 (Mar. 2004). [cited by applicant]
J. Kirchheiner et al., CYP2D6 and CYP2C19 Genotype-Based Dose Recommendations for Antidepressants: A First Step Towards Subpopulation-Specific Dosages, Acta Psychiatrica Scandinavica 104(3):173-92 (Sep. 2001). [cited by applicant]
M.A. Raggi et al., Atypical Antipsychotics: Pharmacokinetics, Therapeutic Drug Monitoring and Pharmacological Interactions, Current Med. Chem. 11(3):279-96 (Feb. 2004). [cited by applicant]
Linda M. Distlerath et al., Purification and Characterization of the Human Liver Cytochromes P-450 Involved in Debrisoquine 4-Hydroxylation and Phenacetin O-Deethylation, Two Prototypes for Genetic Polymorphism in Oxida… [cited by applicant]
Tsutomu Shimada et al., Human Liver Microsomal Cytochrome P-450 Mephenytoin 4-Hydroxylase, a Prototype of Genetic Polymorphism in Oxidative Drug Metabolism, J. Biol. Chem. 261(2):909-921 (Feb. 1986). [cited by applicant]
F. Peter Guengerich et al., Characterization of Rat and Human Liver Microsomal Cytochrome P-450 Forms Involved in Nifedipine Oxidation, a Prototype for Genetic Polymorphism in Oxidative Drug Metabolism, J. Biol. Chem. 2… [cited by applicant]
Rajendrani Mukhopadhyay, Human Cytochrome P450s: The Work of Frederick Peter Guengerich, J. Biol. Chem. 287(19):15798-15800 (May 2012). [cited by applicant]
F. Peter Guengerich et al., Diversity in the Oxidation of Substrates by Cytochrome P450 2D6: Lack of an Obligatory Role of Aspartate 301—Substrate Electrostatic Bonding, Biochemistry 41(36):11025-11034 (2002). [cited by applicant]
A.E. Mutlib et al., Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone, Drug Metab. Dispos. 23(9):951-964 (1995). [cited by applicant]
US FDA, NDA 22-192 (FANAPT® (iloperidone)), Clinical Pharmacology and Biopharmaceutics Review(s), 45 pages (Sep. 27, 2007 and Nov. 6, 2008). [cited by applicant]
J. Kirchheiner et al., Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, Mol. Psychiatry 9:442-473 (2004). [cited by applicant]
Werner Steimer & Julia M. Potter, Pharmacogenetic screening and therapeutic drugs, Clin. Chim. Acta 315(1-2):137-155 (2002). [cited by applicant]
K. Probst-Schendzielorz et al., Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors, Expert Opin. Drug Metab. Toxicol. 11(8):1219-1232 (2015). [cited by applicant]
Paul Rowland et al., Crystal Structure of Human Cytochrome P450 2D6, J. Biol. Chem. 281(11):7614-7622 (2006). [cited by applicant]
Jürgen Brockmöller et al., The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment, Clin. Pharmacol. Ther. 72(4):438-452 (2002). [cited by applicant]
Adrián Llerena et al., “QTc internal lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients,” J. Psychopharmacol. 16(4):361-364 (2002). [cited by applicant]
R. Thanacoody et al., Influence of CYP2D6 genotype on the QTc interval and plasma concentrations of thioridazine and its metabolites in psychiatric patients taking chronic therapy, Clin. Pharmacol. Ther. 73(2):P77 (2003… [cited by applicant]
M. Desai et al., Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6, Pharmacogenomics J. 3:105-113 (2003). [cited by applicant]
Novartis Clinical Study Report, Study No. CILO522 0104, “An open-label study to characterize the pharmacokinetics of iloperidone in poor and extensive 2D6 metabolizers and to evaluate the interaction of iloperidone with… [cited by applicant]
US FDA, NDA 22-192 (FANAPT® (iloperidone)), Pharmacology Review, pp. 1-44 of 89 pages, review submitted to Division File System Jun. 30, 2008. [cited by applicant]
US FDA, NDA 22-192 (FANAPT® (iloperidone)), Pharmacology Review, pp. 45-89 of 89 pages, review submitted to Division File System Jun. 30, 2008. [cited by applicant]
Vanda, Study No. VP-VYV-683-3101, “Treatment-Emergent Adverse Events: By Treatment and Body System” (2007), 2 pages. [cited by applicant]
Urs A. Meyer, Pharmacogenetics and adverse drug reactions, Lancet 356:1667-1671 (2000). [cited by applicant]
Daniel C. Liebler & F. Peter Guengerich, Elucidating Mechanisms of Drug-Induced Toxicity, Nature Rev. Drug Discovery 4:410-420 (2005). [cited by applicant]
Raimundo et al., A novel intronic mutation 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects, Clinical Pharmacology & Therapeutics 76(2):128-138 (2004). [cited by applicant]
A. Gaedigk et al., Deletion of the Entire Cytochrome P450 CYP2D6 Gene as a Cause of Impaired Drug Metabolism in Poor Metabolizers of the Debrisoquine/Sparteine Polymorphism, Am. J. Hum. Drug Genet. 48(5):943-950 (1991). [cited by applicant]
J. Stingl & R. Viviani, Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs, J. Intern. Med. 277:167-177 (2015). [cited by applicant]
F. Peter Guengerich, Role of Cytochrome P450 Enzymes in Drug-Drug Interactions, Adv. in Pharmacol. 43:7-35 (1997). [cited by applicant]
Novartis Pharmaceuticals Corporation, FANAPT® (iloperidone) Label (2014), 20 pages. [cited by applicant]
Novartis Clinical Study Report, Study No. CILO522 2328, “A randomized, open-label, multicenter, 5-arm, safety study evaluating the effect of oral iloperidone at doses of 8 mg b.i.d., 12 mg b.i.d., and 24 mg q.d. on QTc … [cited by applicant]
Novartis Clinical Study Report, Study No. CILO522 2328, “A randomized, open-label, multicenter, 5-arm, safety study evaluating the effect of oral iloperidone at doses of 8 mg b.i.d., 12 mg b.i.d., and 24 mg q.d. on QTc … [cited by applicant]
Novartis Pharmacogenetics Report, Protocol No. CILO522 2328, Study No. PGR-39, “Pharmacogenetics study of CYP2D6 polymorphisms on iloperidone concentration in study ILO522A 2328” 13 pages. [cited by applicant]
Vanda Pharmacogenetics Report, Study No. CILO522 2328-PG-1, “CILO522 2328 PG Report: Single Nucleotide Polymorphisms in the CYP2D6 Gene are Correlated with lloperidone Drug Exposure Levels Impacting the Degree of QTc Pr… [cited by applicant]
Patent Cooperation Treaty, International Search Report and the Written Opinion of the International Searching Authority International Application No. PCT/US2009/056517, 18 pages (Nov. 27, 2009). [cited by applicant]
Caccia, New Antipsychotic Agents for Schizophrenia: Pharmacokinetics and Metabolism Update, Current Opinion in Investigational Drugs, 3(7):1073-1080 (Jul. 2002). [cited by applicant]
Bradford, CYP2D6 Allele Frequency in European Caucasians, Asians, Africans and Their Descendants, Pharmacogenomics 3(2):229-243 (2002). [cited by applicant]
S. Chainuvati et al., Combined Phenotypic Assessment of Cytochrome p450, 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2 and Xanthine Oxidase Activities with the “Cooperstown 5+1 Cocktail”, Clinical Pharmacol. Ther.,… [cited by applicant]
M. L. Dahl et al., Genetic Analysis of the CYP2D Locus in Relation to Debrisoquine Hydroxylation Capacity in Korean, Japanese, and Chinese Subjects, Pharmacogenetics, 5(3):159-164 (1995). [cited by applicant]
A. C. Gough et al., Identification of the Primary Gene Defect at the Cytochrome P 450 CYP2D Locus, Nature, 347:773-776 (Oct. 25, 1990). [cited by applicant]
N. Hanioka et al., The Human CYP2D Locus Associated with a Common Genetic Defect in Durg Oxidation: A G1934—A Base Change in Intron 3 of a Mutant CYP2D6 Allele Results in an Aberrant 3′ Splice Recognition Site, Am. J. H… [cited by applicant]
P. Jaanson et al., Maintenance Therapy with Zuclopenthixol Decanoate: Associations Between Plasma Concentrations, Neurological Side Effects and CYP2D6 Genotype, Psychopharmacology, 162:67-73 (2002). [cited by applicant]
K. K. Jain, An assessment of iloperidone for the treatment of schizophrenia, Expert Opin. Investig. Drugs, 9(12):2935-2943 (Dec. 2000). [cited by applicant]
I. Johansson et al., Genetic Analysis of the Chinese Cytochrome P4502D Locus: Characterization of Variant CYP2D6 Genes Present In Subjects with Diminished Capacity for Debrisoquine Hydroxylation, Molecular Pharmacology,… [cited by applicant]
M. Kagimoto et al., Multiple Mutations of the Human Cytochrome P45011D6 Gene (CYP2D6) In Poor Metabolizers of Debrisoquine, The Journal of Biological Chemistry, 265(28):17209-17214 (1990). [cited by applicant]
J. P. Kelleher et al., Advances in Atypical Antipsychotics for the Treatment of Schizophrenia: New Formulations and New Agents, CNS Drugs, 16(4):249-261 (2002). [cited by applicant]
V. Lyamichev et al., Polymorphism Identification and Quantitative Detection of Genomic DNA by Invasive Cleavage of Oligonucleotide Probes, Nat. Biotechnol., 17(3):292-296 (Mar. 1999). [cited by applicant]
S. McElroy et al., CYP2D6 Genotyping as an Alternative to Phenotyping for Determination of Metabolic Status in a Clinical Trial Setting, AAPS PharmSci, 2(4):1-11 (Oct. 29, 2000). [cited by applicant]
A. E. Mutlib et al., Application of Liquid Chromatography/Mass Spectrometry in Accelerating the Identification of Human Liver Cytochrome P450 isoforms Involved in the Metabolism of iloperidone, J. Pharmacol. Exper. Ther… [cited by applicant]
M. Nevilie et al., Characterization of Cytochrome P450 2D6 Alleles Using the Invader System, BioTechniques, Suppl:34-8, 40-3 (Jun. 2002). [cited by applicant]
N. Subramanian et al., Receptor Profile of P88-8991 and P95-12133, Metabolites of the Novel Antipsychotic Iloperidone, Prog. Neuropsychopharmacol. Biol. Psychiatry, 26(3):553-560 (2002). [cited by applicant]
H. Yokota et al., Evidence for a New Variant CYP2D6 Allele CYP2D6J in a Japanese Population Associated with Lower In Vivo Rates of Sparteine Metabolism, Pharmacogenetics, 3(5):256-263 (1993). [cited by applicant]
Home p. of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee, (www. cypalleles.ki.se/) (May 2008). [cited by applicant]
R. P. Sheridan et al., Empirical Regioselectivity Models for Human Cytochromes P450 3M, 2D6, and 2C9, J. Med. Chem. 50(14): 3173-3184 (Jun. 2007). [cited by applicant]
D. Ryan et al., Non-PCR-Dependent Detection of the Factor V Leiden Mutation From Genomic DNA Using a Homogeneous Invader Microtiter Plate Assay, Mol. Diagn., 4(2):135-144 (1999). [cited by applicant]
T. Shimada et al., Characterization of (+/−)-Bufuralol Hydroxylation Activities in Liver Microsomes of Japanese and Caucasian Subjects Genotyped for CYP2D6, Pharmacogenetics 11(2):143-156 (2001). [cited by applicant]
S. Fuselli et al., Molecular diversity at the CYP2D6 locus in the Mediterranean region, Eur. J. Hum. Genet., 12(11):916-924 (Nov. 2004). [cited by applicant]
C. Sachse et al., Cytochrome P450 2D6 in a Caucasian Population: Allele Frequencies and Phenotypic Consequences, Am. J. Hum. Genet., 60(2):284-295 (Feb. 1997). [cited by applicant]
S. L. Wang et al., G169R Mutation Diminishes the Metabolic Activity of CYP2D6 in Chinese, Drug Metab. Dispos., 27(3):385-388 (Mar. 1999). [cited by applicant]
S. M. Sainati, Safety, Tolerability, and Effect of Food on the Pharmacokinetics of Iloperidone (HP 873), a Potential Atypical Antipsychotic, J. Clin. Pharmacol. 35(7):713-720 (1995). [cited by applicant]
C. L. Alfaro et al., CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations, J Clin Pharmacol. 40(1):58-66 (2000). [cited by applicant]
S. M. Cheer et al., Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness, Drugs 61(1):81-110 (2001). [cited by applicant]
Novartis Pharmaceuticals Corporation, Fanapt Full Prescribing Information (20 pages) (Apr. 2014). [cited by applicant]
Vanda Pharmaceuticals Inc., Fanapt (iloperidone) Tablets Full Prescribing Information (23 pages) (May 2009). [cited by applicant]
Janssen Pharmaceutica Products, LP, Risperdal (Risperidone) Tablets/Oral Solution< Risperdal M-Tab™ (Risperidone) Orally Disintegrating Tablets Risperdal® (risperidone) Label (2003), 34 pages. [cited by applicant]
Dan M. Roden, Drug-induced prolongation of the QT interval, N Engl J Med. 350(10):1013-22 (2004). [cited by applicant]
[cited by applicant]